CBD In Europe, The Current State Of Play With Canna’s Steve Oliver
In this episode of the Over The Counter podcast, HBW Insight catches up with cannabis expert Stephen Oliver to talk about the current state of play in Europe’s cannabidiol markets.
Please wait, loading...
In this episode of the Over The Counter podcast, HBW Insight catches up with cannabis expert Stephen Oliver to talk about the current state of play in Europe’s cannabidiol markets.
CBD products linked to a submitted, rather than validated, novel food application can now remain on the UK market after 31 March, according to new guidance from regulator the Food Standards Agency.
Europe’s hemp industry hit a milestone last week when the European Union’s top court liberated CBD from the jurisdiction of an international drug treaty, declaring that hemp-derived cannabidiol is not a narcotic.
In May we published an analysis of the Judgement of Advocate General Tanchev in respect of the Kanavape case, “Can the movement of CBD within the European Member States be prohibited it if is derived from prohibited elements of the plant?”. We observed that there was “good” and “bad” in the provisional Opinion.
Stephen Oliver former Customs Investigator and Matt Lawson Barrister are both experts in the cannabinoid industry, they are the founders of The Canna Consultants and will be speaking at the event on both days.
Stephen Oliver and Matt Lawson are both experts in the cannabinoid industry, they are the founders of The Canna Consultants and will be speaking at the Cannabis Investment Summit World (CISW) which takes place 11-13 of November 2020.
We have reproduced the questions as they have been submitted in order not to interfere with them. If you are unable to answer the question as drafted, we would encourage you to answer what you feel is the import of the question in order that market participant is not disadvantaged by potentially poor language selection in their phraseology.
Is the FSA's policy that any CBD "New to Market" products will be treated differently than those "Already on the Market" justified despite there being no difference in their potential risks? Perhaps the more telling question is whether the policy will be sustained in the face of an inevitable legal challenge?
In May we published an analysis of the Judgement of Advocate General Tanchev in respect of the Kanavape case, “Can the movement of CBD within the European Member States be prohibited it if is derived from prohibited elements of the plant?”
The recent news that Mike Harlington, the now ex-Chairman of the CTA, has been ousted by the organisation’s board (now led by Tom Whettem) was reported by The Canna Consultants here. The news led us to take a delve into TrustCanna... and what did we find?